# Ensuring Faster Access to Effective Multiple Sclerosis Medications

California

Bahar Davidoff, VP of Pharmacy, Bdavidoff@regalmed.com Regal Medical Group, Northridge, Regalmed.com

# Project Description


A population health pharmacist led program for Multiple Sclerosis to integrate guideline-directed clinical assessment and diagnosis, formulary and benefit information, and patient reported outcome surveys to ensure timely dispensing of the most effective therapeutic option resulting in reduction in cost of care and delayed disease progression.


#### **Problem Statement:**

MS patients have the fourth highest Per Member Per Month. We had a 44% annual growth rate in ER visits year over year. 24% Nonadherence with medication.

### Discovery:

To find out why there was an increase in ER visits and the reason for the 24% non-adherence I started by interviewing nine neurologist and realized that there are major obstacles that resulted in delayed medication access for the patients. I discovered the average time of access to medication from diagnosis was 90 days. After interviewing thirteen patients, I found out that the patients were going to the ER due to relapse symptoms. I interviewed seven more neurologist and it was evident that the relapses and symptoms bringing the patients to the ER was due a delay in starting medications. I then developed a program to remove the barriers and get the patients on effective medications in a timely manner.






#### Goal:


Ensure that MS patients receive the most effective medication with in a month of diagnosis to reduce relapses and disease progression leading to inpatient utilization.

### **Outcome-oriented Objective:**

- Reduce annual MS ER and Hospitalization cost by 26% by July 2018 compared the year before
- Increase adherence by 15% by July 2018 compared to the year before

## Results





# Lessons Learned

- The project needs a longer data collection period to be able to assess the primary end point of reducing relapse and MRI disease progression results.
- For the future projects I would recommend interviewing the people that will be affected by the initiative (patients) rather than the people who will implement it (physicians).
- I would also look into modalities that are currently out there that can be enhanced rather than do it from the beginning.
- This projects enabled my organization to realize that we need to address the whole picture for the cost of care for chronic disease patients rather than look at the medication cost, in patient utilization costs in silos. This way we were able to identify the root cause of the issues and rectify them.

### **Next Steps:**

- Project will need to be embedded into a platform for utilization by neurologist at the time of prescribing.
- I will meet with Epic and Cerner to adopt this protocol into their system.
- Protocol should be developed for other chronic diseases with high cost medications such as Rheumatoid Arthritis, Psoriasis, and Ulcerative Colitis.

# Mission Model Canvas

#### **Key Partners Key Activities** Value Propositions Buy-in & Support Neurologist Develop MS evidence-based Help Neurologist and MS Neurologist- Education sessions protocols incorporating HP patients find the most effective and materials MS patients formularies and patient formulary medication resulting Letters to patients about this in 20% reduction in ER and treatment preferences program Provide information to hospitalization costs Office staff education about neurologist at the point of patient surveys Reduce MD frustration and prescribing time spent on PA by half Key Resources Deployment Ensure that patients receive Prior Auth portal Neurologist specialized in more effective medication Journal of Neurology faster resulting in Reduction of American Academy of Pharmacists development of relapse and MRI brain lesions neurology protocols and Patient American Neurological reported outcome survey Association MS Patients National MS Society

#### Mission Budget/Cost

- Consultant Neurologist cost- \$20,000
- Pharmacist cost- \$115,000

## Payer

**6** 

Beneficiaries

MS Patients

Neurologist

- Mission Achievement/Impact Factors
- \$129,000 cost savings for ER and hospitalizations in 9 months for 43 Patients
- %15 increase in medication adherence
- Reduced average time of initiation of medication by 75% (4x faster)

